Search

everythinglearnresearchcommunity

for

Search:↓

PP405 shows promising results for hair density improvement, potentially outperforming Minoxidil in a shorter time. However, its public release is expected around 2029/2030, and its cost and availability remain uncertain.

The conversation is about when the phase 3 results for pyrilutamide, a potential hair loss treatment, will be released. There was a letter about the study a month ago, but the actual results were not included.

A 17-year-old is addressing hair loss with finasteride, topical minoxidil, and microneedling. They are considering adding GHK-Cu to their regimen, but others advise caution with finasteride due to age.

The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

Efforts to find a Canadian dermatologist in the US to prescribe H&W's topical finasteride for hair loss. The user is willing to fund a crowd-share effort to identify prospects.

A hair restoration case involved injecting four different doses of Verteporfin into the mid scalp and using Scalp MicroPigmentation (SMP) around the extraction areas. Photos were taken and an update will be shared soon.

A 26-year-old male is still experiencing hair loss after a year of using Dutasteride and is considering using CB0301 (Breezula) to block all androgens on his follicles. He is looking for a reliable source to purchase CB0301 and inquires about the availability of a premade solution.

The conversation is about obtaining pyrilutamide for hair loss treatment from China through a contact, with details on pricing and shipping. The user offers to facilitate the purchase and shipment for a small commission.

The user is hesitant to use finasteride due to potential hormonal side effects and is waiting for the release of pyrilutamide, a new hair loss treatment. Other users suggest trying finasteride, warning about potential regret if hair loss progresses in the meantime.

A 28-year-old shared surprising hair regrowth progress after 20 days using topical minoxidil, micro needling, GHK-cu, and BPC-157 injections. The user noted a significant reduction in their bald spot and overall hair improvement.

The conversation is about the anticipated results of Pelage's Phase 2a clinical trial for their topical hair loss treatment, PP405. Users speculate on when the results will be available, noting that delays might indicate less successful outcomes.

HMI-115, a potential treatment for hair loss that has been reported to produce significant regrowth in bald areas. It is the closest thing to a cure currently available and has raised hope that it could make hair transplants obsolete.

The user has been using Actifolic Pyrilutamide 0.5% once daily for almost three weeks without noticing any side effects or progress. Other users suggest that significant results typically take 3-6 months to appear.

PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.

A user shared their 9-month progress using RU58841 at 2% daily for hair regrowth, initially starting at 5% but reducing the dose due to early signs of gynecomastia, which has since mostly resolved. They achieved their goal of regrowing hair at the temples and hairline.

TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.

CB-03-01 (Breezula) powder for hair loss. Users discuss its availability and seek feedback on its effectiveness.

A 25-year-old is experiencing chronic telogen effluvium (TE) and androgenetic alopecia (AGA) after surgery, using finasteride, red light therapy, and supplements, and considering oral minoxidil despite heart concerns. They are unsure whether to start minoxidil before or after an upcoming surgery, which may trigger another hair shed.

The conversation is about using oral finasteride and minoxidil for hair loss, with consideration of adding topical GHK-Cu for skin and hair benefits. The user seeks opinions on this combination.

A 35-year-old shared a 7-day update on their hair transplant, which involved 3,153 grafts performed by Dr. Elif at HLC Ankara, costing 10,000 euros including accommodations. The user has been on finasteride for over 12 years and opted for a partial shave FUE to address hairline recession and temple peaks.

The conversation discusses using GHK-Cu, C60, and saw palmetto oil as treatments for hair loss. Specific treatments mentioned include Minoxidil (Min), Finasteride (Fin), and RU58841 (RU).

The Phase 2 trial for Pyrilutamide in the US, which started a year after the China trials, and inquiring about any available information on when it will finish. Treatments discussed include Minoxidil, Finasteride, and RU58841.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

The user experiencing diffuse hair loss is using various treatments including RU58841, finasteride, minoxidil with tretinoin, anti-hair loss shampoo, and microneedling, and is considering adding peptides TB500, BPC157, and GHK-Cu. They have low growth hormone levels and are questioning its impact on hair loss, while another user suggests androgenic alopecia and androgens are likely the main cause of hair loss.

People are discussing their experiences with kx-826 (pyrilutamide) for hair loss, using concentrations of 0.5% and 0.9%. They are sharing personal results and progress with this treatment.

The conversation discusses the potential benefits and risks of participating in the PP405 hair loss trials, emphasizing that those using Minoxidil or finasteride are less likely to be accepted. Participants are interested in the trial as it offers hope for effective treatment without the side effects associated with current medications.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.

Significant hair regrowth was achieved using EssenGen 6-Plus with 6% minoxidil and 0.05% finasteride, along with Nizoral shampoo, over 12 weeks. No side effects were experienced, highlighting the benefits of a low dose.